John Dewar & Sons Ltd., one of the most respected names in the world of Scotch whisky, today announced plans to release a range of new expressions and never-before-released single malts – the hidden gems of its single malt portfolio. This bold move, unprecedented in recent years, will introduce a treasure trove of top-shelf whiskies to consumers around the world.
The distinguished drams of ABERFELDY®, AULTMORE®, CRAIGELLACHIE®, THE DEVERON® and ROYAL BRACKLA® are launched under the title of the “Last Great Malts,” each with a compelling story and character.
For generations, these distinctive whiskies have been distilled and left to mature undisturbed in oak casks. Now, at last, whisky aficionados the world over will be able to taste the single malts from these distilleries in their authentic form.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/72762539-Last-Great-Malts-Scotch-Whisky/
George Freeman MP, the Minister for Life Sciences, will give the keynote address at the 3rd Astellas Innovation Debate: i-Genes – What the DNA and Data Revolutions mean for our Health, taking place on Thursday 29th January 2015 at the Royal Institution of Great Britain.
Organised and funded by Astellas, a progressive pharmaceutical company that explores the frontiers of scientific discovery to translate new knowledge into innovative, reliable medicines, the Astellas Innovation Debates are a series of annual events that bring together some of the world’s most progressive thinkers to discuss the role of innovation in solving some of the greatest challenges of our time.
George Freeman’s keynote address will outline the Government’s aim to develop, assess and adopt new drugs, devices and diagnostics as we move towards 21st century, personalised healthcare.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7423951-george-freeman-astellas-debate/
Barrister, peer and Vice-President of the Patients Association Baroness Helena Kennedy has joined a panel of internationally recognised experts for the 3rd Astellas Innovation Debate: i-Genes – What the DNA and Data Revolutions mean for our Health, taking place on Thursday 29th January 2015 at the Royal Institution of Great Britain.
Organised and funded by Astellas, a progressive pharmaceutical company that explores the frontiers of scientific discovery to translate new knowledge into innovative, reliable medicines, the Astellas Innovation Debates are a series of annual events that bring together some of the world’s most progressive thinkers to discuss the role of innovation in solving some of the greatest challenges of our time.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7424051-helena-kennedy-astellas-debate/
Personalised Medicine is the future of cancer treatment, but it presents major challenges for doctors and health services, the President of the European Society of Medical Oncology has said. Professor Rolf Stahel was speaking ahead of the 3rd Astellas Innovation Debate: i-Genes – What the DNA and Data Revolutions mean for our Health, taking place on Thursday 29th January 2015 at the Royal Institution of Great Britain.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7430351-professor-rolf-stahel-astellas-debate/
Advanced technology has the power to transform healthcare, a world leader in the field of genomicsDr Leroy Hood, has said ahead of the 3rd Astellas Innovation Debate: i-Genes – What the DNA and Data Revolutions mean for our Health, taking place on Thursday 29th January 2015 at the Royal Institution of Great Britain.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7430051-dr-leroy-hood-astellas-debate/
Professor Lionel Tarassenko, CBE, Head of Engineering at the University of Oxford and Fellow of the Royal Academy of Engineering and the Academy of Medical Sciences, has joined a panel of internationally recognised experts for the 3rd Astellas Innovation Debate: i-Genes – What the DNA and Data Revolutions mean for our Health, taking place on Thursday 29th January 2015 at the Royal Institution of Great Britain.
As the worlds of science and technology come together, the 2015 Astellas Innovation Debate, organised and funded by Astellas, will discuss recent breakthroughs in genetic medicine and smart technology, and what they mean for our health.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7432051-lionel-tarassenko-astellas-debate/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Last Tuesday night, Laetitia Casta and La Maison Cointreau announced the launch of the Cointreau Creative Crew in the Pompadour Ballroom at the Hotel Café Royal in London. A worldwide philanthropist programme curated by Creative Director Laetitia Casta, the Cointreau Creative Crew aims to develop women’s freedom and encourage them to make their dreams a reality. Launching for the first time in the UK, this programme will culminate in one entrepreneur being awarded a £20,000 bursary to support their creative project which will be announced in Spring 2016.
Decorated with Cointreau elegantly dressed in soft furnishings and floral arrangements, the Pompadour Ballroom played host to 150 guests on the night. The former French model looked stunning and was joined on the night by a host of A-list celebrities including Ella Eyre, Donna Air, Charlie XCX and Laetitia Casta. Additional guests in attendance included CEO of Rémy Cointreau Valérie Chapoulaud-Floquet, established fashion philanthropist Nick Ede, Managing Director of Liberty of London Ed Burstell and Editor of Glamour UK Jo Elvin.
To view the Multimedia News Release, go to http://www.multivu.com/players/uk/7677251-laetitia-casta-cointreau-creative-crew/
Over the summer, architects, contractors and designers have been busy with an incredible home transformation on the sunny coast of Florida to bring fans the first ever HGTV® Dream Home Giveaway renovation. The sneak peek at this beautiful, one-of-a-kind makeover is now available at hgtv.com/hgtvdreamhome.
The waterfront property is shaded by giant royal palm trees and situated on the Indian River Lagoon with Intracoastal Waterway access. The updated, transitional take on Floridian style offers casual elegance with a clever play on classic coastal. The light and bright paradise is built for entertaining and relaxing by the water, complete with a private pool and a three-car garage. With approximately 3,150 square feet of living space, including three bedrooms and five bathrooms, the home blends the sophistication of the Hamptons with punches of tropical vibrancy.
To view the multimedia release go to:
http://www.multivu.com/players/English/7687151-hgtv-dream-home-2016-renovation/
MYRA School of Business is a boutique business school located in the royal city of Mysore—an educational hub and a heritage city. Mysore Royal Academy (MYRA) established in 2010 has set up the MYRA School of Business. Committed to excellence in everything we do—faculty, pedagogy, and campus, MYRA has created a unique learning platform called the Immersion Learning Model. The award winning campus inaugurated by Deepak Parekh, Chairman HDFC, in 2012 not only fosters learning but adds to the Joie de vivre.
MYRA offers four different Academic Programs—the two-year AICTE approved-fulltime Post Graduate Diploma in Management (PGDM); one-year fulltime Post Graduate Program for eXecutives (PGPX); Executive Education Programs; and PhD program (University of Mysore). With a pedagogy focused on live case studies, practicums that bring real-world challenges into the classroom and global faculty, the learning experience at MYRA is truly unique. This, along with a variety of industry interactions and programs that facilitate their campus-to-corporate transition, result in “MYRAcles” who are ‘job ready’ and productive from day one of their careers.
To view the multimedia release go to:
http://www.multivu.com/players/uk/7774851-myra-school-of-business-management-students/
MYRA, career, school, education, Academic, students, higher education, collage, University, MultiVu 7774851
